LigaChem Biosciences Inc.
Financials
Valuation Metrics
LigaChem Biosciences Inc.'s Market Cap is ₩2.3T. At end of 2025 it was ₩6.4T. Ranked #170 of 2,414 in KR market (top 7%), #25 of 1,633 on KOSDAQ (top 2%), #11 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 5%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.33T KRW | KR#170/2,414 Sec#11/231 |
| Revenue | 98.78B KRW | KR#1,425/2,414 Sec#88/231 |
| Net Income | -181.37B KRW | KR—/2,414 Sec—/231 |
| Total Assets | 701.81B KRW | KR#611/2,414 Sec#34/231 |
| Net Assets | 541.12B KRW | KR#482/2,414 Sec#30/231 |
| Employees | 174 | KR#1,195/2,414 Sec#99/231 |
| Value | ||
| P/B | 4.31x | KR#2,215/2,414 Sec#186/231 |
| P/S | 23.61x | KR#2,342/2,414 Sec#188/231 |
| FCF Yield | -5.47% | KR—/2,414 Sec—/231 |
| Profitability | ||
| ROE | -33.52% | KR#2,208/2,414 Sec#184/231 |
| ROA | -25.84% | KR#2,280/2,414 Sec#191/231 |
| Op. Margin | -208.25% | KR#2,329/2,414 Sec#185/231 |
| Revenue Growth | -33.38% | KR#2,231/2,414 Sec#199/231 |
| Financial Health | ||
| Debt Ratio | 29.70% | KR#585/2,414 Sec#66/231 |
| Total Debt | 0 KRW | KR—/2,414 Sec—/231 |
| FCF | -127.58B KRW | KR#2,146/2,414 Sec#212/231 |
| Cash | 98.65B KRW | KR#474/2,414 Sec#23/231 |
| Current Ratio | 9.37x | KR#111/2,414 Sec#27/231 |
| Performance | ||
| 1Y Return | -56.28% | KR#2,115/2,414 Sec#197/231 |
| 1M Return | -24.19% | KR#2,251/2,414 Sec#217/231 |
| From 52W High | -72.00% | KR#2,152/2,414 Sec#187/231 |
| 1Y MDD | -70.49% | KR#2,003/2,414 Sec#174/231 |
| Trading | ||
| Volume | 208,287 shares | KR#570/2,414 Sec#54/231 |
| Trading Value | 13.12B KRW | KR#227/2,414 Sec#15/231 |
| Foreign Own. | 12.63% | KR#391/2,414 Sec#28/231 |
| Per Share | ||
| EPS | -4,899 KRW | KR—/2,414 Sec—/231 |
| BPS | 14,617 KRW | KR#716/2,414 Sec#47/231 |
Company Info
LegoChem Biosciences, established in 2006 and headquartered in Yuseong-gu, Daejeon, is a research-oriented pharmaceutical company listed on KOSDAQ in 2013. The company developed the medicinal chemistry-based original Antibody-Drug Conjugate (ADC) technology named ConjuALL, driving global commercialization through ADC anticancer drug research and development and technology transfer. Through "Beyond ADC" research, it focuses on developing bispecific antibody ADCs, immuno-oncology drugs, and combination therapies, while also securing stable revenue from medical device and consumable sales.